Literature DB >> 178852

Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants.

P F Wright, T Shinozaki, W Fleet, S H Sell, J Thompson, D T Karzon.   

Abstract

Respiratory syncytial virus ts-1 is a live attenuated experimental vaccine which was administered intranasally to 25 infants 11 to 19 months of age. Clinical evaluation was carried out following a controlled, double-blind protocol which eliminated observer bias, assessed intercurrent illness, and was designed to detect virus transmission. At the low dose of virus of virus used (100 TCID50) 8 of the 25 recipients were successfully infected with RS virus ts-1 as determined by virus shedding or antibody response.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 178852     DOI： 10.1016/s0022-3476(76)81044-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  26 in total

1.  Location of a highly conserved neutralizing epitope in the F glycoprotein of human respiratory syncytial virus.

Authors:  J A López; C Peñas; B García-Barreno; J A Melero; A Portela
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

2.  Viral vaccines: the use of currently available products and future developments.

Authors:  E Norrby
Journal:  Arch Virol       Date:  1983       Impact factor: 2.574

3.  Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature.

Authors:  Cindy Luongo; Christine C Winter; Peter L Collins; Ursula J Buchholz
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

Review 4.  Vaccines for the common cold.

Authors:  Daniel Simancas-Racines; Juan Va Franco; Claudia V Guerra; Maria L Felix; Ricardo Hidalgo; Maria José Martinez-Zapata
Journal:  Cochrane Database Syst Rev       Date:  2017-05-18

Review 5.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

6.  Interferon production by human mononuclear leukocytes: differences between respiratory syncytial virus and influenza viruses.

Authors:  T Chonmaitree; N J Roberts; R G Douglas; C B Hall; R L Simons
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

7.  Live-attenuated respiratory syncytial virus vaccines.

Authors:  Ruth A Karron; Ursula J Buchholz; Peter L Collins
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

8.  Correlation of proliferation of lung epithelium with intramuscular sensitization and complement-fixing antibody to respiratory syncytial virus in the golden hamster.

Authors:  H V Ratajczak; D O Lucas; L M Kelley; S E Wilson
Journal:  Clin Exp Immunol       Date:  1981-09       Impact factor: 4.330

9.  Rational design of human metapneumovirus live attenuated vaccine candidates by inhibiting viral mRNA cap methyltransferase.

Authors:  Yu Zhang; Yongwei Wei; Xiaodong Zhang; Hui Cai; Stefan Niewiesk; Jianrong Li
Journal:  J Virol       Date:  2014-07-23       Impact factor: 5.103

10.  Inactivation of respiratory syncytial virus by zinc finger reactive compounds.

Authors:  Marina S Boukhvalova; Gregory A Prince; Jorge C G Blanco
Journal:  Virol J       Date:  2010-01-26       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.